Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipients.
Date:
04/07/2022
Citation:
Strauss AT, Chang A, Alejo JL, Chiang TP, Hernandez NF, Zeiser LB, Boyarsky BJ, Avery RK, Tobian AAR, Levan ML, Warren DS, Massie AB, Garonzik-Wang JM, Segev DL, Werbel WA. Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipients. Liver Transpl. 2022 Apr 7:10.1002/lt.26472. doi: 10.1002/lt.26472. Epub ahead of print. PMID: 35389558; PMCID: PMC9088577.
Abstract
To the Editor: Liver transplantation (LT) recipients have attenuated antibody response to the two-dose messenger RNA (mRNA) vaccine series against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[ 1 , 2 , 3 ] Additional vaccine doses, best studied in the kidney transplantation population, may improve response, yet many solid organ transplantation recipients appear to continue to have a poor response despite additional doses.[ 4 , 5 ] We aimed to measure antibody levels before and after a third mRNA vaccine dose (D3) in a large cohort of LT recipients to understand vaccine immunogenicity and the demographic, transplantation, and vaccine type associated with sero-response.